1. Why, When, and How to Switch ART in Patients With HIV Who Have Achieved Viral Suppression

2. Program Overview

4. Reasons to consider switching in virologically suppressed Patients with HIV

5. Reasons for Switching in Virologically Suppressed Patients

6. Switching Categories in Virologically Suppressed Patients

7. Reasons for Switching in Asymptomatic Patients

8. Further Reasons for Switching

9. Don’t Fix It If It Ain’t Broken… Except To…

10. Issues to Consider Before Switching

11. Considerations After Decision to Switch

12. Considerations After Decision to Switch (cont)

13. A Menu of Switches….

14. ARDENT Trial

15. Reasons for Switching Determine Therapeutic Choice

16. Coinfected Patients

17. Ongoing Dolutegravir Switch Studies

18. Ongoing Raltegravir Switch Studies

19. Ongoing Elvitegravir Switch Studies

20. New Switching Data at IAS, Vancouver

21. New Switching Data at ICAAC, San Diego

22. Upon Deciding to Switch: What Are the Key Considerations?

23. Regional Considerations

24. Conclusions

25. Abbreviations

26. Abbreviations (cont)

27. References